Close Menu

asset sale

Based in Boston with operations in Ireland and Iceland, the reorganized company is supporting COVID-19 testing and population genomics as it sheds its China division.

The company turned its first-ever quarterly profit after a series of asset sales and cutbacks in money-losing molecular tests. 

The company trimmed its net loss fell by three-fourths to $11.8 million in the quarter as it continues to rein in costs.

The firm also said it is contemplating selling its therapeutics division, and appointed David Bench as its new CFO.

The firms are also partnering to develop molecular diagnostic assays and for the supply of enzymes and oligonucleotides required for manufacturing.

Divesting the cord blood business will allow Natera to focus on its genetic testing business in reproductive health, oncology, and organ transplantation.

The San Francisco-based microbial genomics firm will sell off its product lines, testing labs, IP, and data within the next three months.

EdiGene has developed a diploid library of 2,800 single clonal knockout cell lines, targeting 2,600 genes in commonly used human cancer cell lines.

Locus said it will pair the EpiBiome platform with its own CRISPR-based synthetic biology system to develop products that can edit the microbiome.

The firm is selling BioServe to Reprocell as part of Cancer Genetics' transformation and strategic plan to bring itself to profitability.

Pages

UK Royal Statistical Society is organizing a working group to develop guidelines for assessing COVID-19 tests, the Guardian reports.

The Washington Post reports that the White House chief of staff has asked the US Food and Drug Administration to justify the stricter standards it is seeking for a coronavirus vaccine.

President Donald Trump's "good genes" comment raises eugenics concerns, CNN reports.

In PLOS this week: genetic analysis of tremor condition, analysis of a West and Central African tree used in traditional medicine, and more.